Composite containing collagen and elastin as a dermal expander and tissue filler
View Patent ↗An injectable composition having dermal filling and tissue expanding activity comprises: (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion; and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen; in other alternatives, the composition can further comprise hyaluronic acid; and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly. The elastin, however, is the primary filler, even if collagen or hyaluronic acid are included in the composition.
1. An injectable composition having dermal filling and tissue expanding activity consisting essentially of:
(a) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion; and
(b) a pharmaceutically acceptable carrier, wherein the carrier comprises an excipient selected from the group consisting of glucose, maltose, and carboxymethylcellulose;
wherein the composition provides space filling activity owing to the quantity of elastin;
wherein the quantity of elastin is from 20 mg/mL to 300 mg/mL; and
wherein the elastin is full-length elastin.
2. The composition of claim 1 wherein the elastin is selected from the group consisting of non-human mammalian elastin and human elastin.
3. The composition of claim 1 wherein the pharmaceutically acceptable carrier comprises gelatin.
4. The composition of claim 1 wherein the composition further comprises a rapid-acting local anesthetic selected from the group consisting of lidocaine, benzocaine, tetracaine, bupivacaine, etidocaine, flecainide, mepivacaine, pramoxine, prilocaine, chloroprocaine, proparacaine, ropivacaine, dyclonine, dibucaine, propoxycaine, chloroxylenol, cinchocaine, dexivacaine, diamocaine, hexylcaine, levobupivacaine, pyrrocaine, risocaine, and rodocaine.
5. The composition of claim 4 wherein the rapid-acting local anesthetic is lidocaine.
6. The composition of claim 1 wherein the elastin is crosslinked with a cross-linking agent selected from the group consisting of a compound that is a member of the class of proanthocyanidins, a bifunctional epoxide, a carbodiimide, and glutaraldehyde.
7. The composition of claim 6 wherein the cross-linking agent is a compound that is a member of the class of proanthocyanidins.
8. The composition of claim 7 wherein the compound that is a member of the class of proanthocyanidins is selected from the group consisting of proanthocyanidin, procyanidin (2H-1-benzopyran-3,4,5,7-tetrol, dihydroxyphenyl)-2-((2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl)oxy)-3,4-dihydro), procyanidin B, procyanidin B2, rhatannin, procyanidol oligomer, procyanidin C, procyanidin B3, procyanidin B1, selligueain A (8,14-methano-2H,14H-1-benzopyrano(7,8-d)(1,3)benzodioxocin-3,5,11,13,15-pentol, 4-(3,4-dihydro-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-8-yl)-3,4-dihydro-2,8-bis(4-hydroxyphenyl)-, (2R-(2α,3α,4β(2R*,3S*),8β,14β,15R*)), geranin A, geranin D, procyanidin B5, procyanidin B5-3′-O-gallate, vitisinol, amurensisin, terminalin, geranin B, 6,8-dihydroxyafzelin, afzelin-3″-O-gallate, geranin C, afzelin, flavangenol, carallidin, mahuannin A, proanthocyanidin A1, proanthocyanidin A2, and procyanidin D.
9. The composition of claim 8 wherein the compound that is a member of the class of proanthocyanidins is proanthocyanidin.
10. The composition of claim 6 wherein the cross-linking agent is a bifunctional epoxide and wherein the bifunctional epoxide is 1,4-butanediol diglycidyl ether.
11. The composition of claim 6 wherein the cross-linking agent is a carbodiimide selected from the group consisting of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide iodide (EAC); 1-cyclohexyl-3-(2-morpholinyl-(4)-ethyl-carbodiimide metho-p-toluenesulfonate (CMC), and N-benzyl-N′-3-dimethylaminopropylcarbodiimide hydrochloride (BDC).
12. The composition of claim 6 wherein the cross-linking agent is selected from the group consisting of glutaraldehyde and periodate.
13. The composition of claim 1 wherein the elastin is crosslinked with a glycosaminoglycan selected from the group consisting of hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dermatan sulfates, heparin, heparan sulfates, and keratan sulfates.
14. The composition of claim 1 wherein the elastin is cryofractured into a fine particle.
15. The composition of claim 1 wherein the pharmaceutically acceptable carrier comprises carboxymethylcellulose.